Mallinckrodt plc Ordinary Share (NYSE:MNK):
Mallinckrodt Pharmaceuticals Donates Drug Deactivation Pouches to Enable Safe Disposal of Prescription Drugs in South Carolina.
The company is now down since yesterday’s close of $63.04.
It is currently trading at $61.38 marginally under $69.45, the stock’s 50 day moving average and which is marginally lower than the 200 day moving average of $66.80. The 50 day moving average was down $-8.07 whereas the 200 day moving average was down $-5.42 or -8.12%.
The P/E ratio is currently 11.57 and the market value is 6.61B. As of the last earnings report the EPS was $5.30 and is projected to be $7.64 for the current year with 107,713,000 shares presently outstanding. Next quarter’s EPS is expected be $1.90 and the next full year EPS is anticipated to be $8.09.
A few brokerage firms have released opinions on the stock recently. August 31 investment analysts at Deutsche Bank maintained a company rating of “Buy” but moved down the price target to $84.00 from $87.00. On August 25 Barclays made no change to the company rating of “Overweight” and raised the price target from $80.00 to $112.00.
August 24 investment analysts at Piper Jaffray kept the stock rating at “Overweight” and moved up the price target from $102.00 to $112.00. Equity analyst Stifel Nicolaus initiated coverage on the stock with an initial rating of “Buy”.
On June 29 analysts at BMO Capital initiated coverage on MNK with a rating of “Outperform”. May 4 investment analysts at JP Morgan left the stock rating at “Neutral” but lowered the price expectation to $85.00 from $120.00.